Dr. Zhuang and Dr. Wang introduce a modified peptide inhibitor of CDK5/p25 complex activity that can treat cancers (e.g., glioblastoma and colon cancer) causing abnormal regulation of central nervous system (CNS) processes.
BOSTON (PRWEB) January 31, 2021
For this breakthrough science to treat colon cancer and glioblastoma, One Million Solutions in Health via their Hidden GEMS Program partnered with the United States' National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to spread awareness of NIH technologies and advances, to commercialize this new science through licensing agreements.
Dr. Zhengping Zhuang and Dr. Herui Wang share their work in this scientific presentation and licensing opportunity review which is spearheaded by One Million Solutions in Health. During this presentation which is entitled “NIH Licensing Opportunity: Breakthrough Science to Treat Colon Cancer and Glioblastoma” scientific scouts, business leaders and commercialization experts are provided with the opportunity to acquire knowledge about the latest science and technology directly from these NIH scientists.
In this scientific and opportunity presentation, those attendees with strong knowledge about this market and the scientific need for new technology can also take part in One Million Solutions in Health's exclusive Signature Square process where they are able to assess the innovation, make inquiries and give open feedback to the scientist.
This licensing opportunity introduces a modified peptide inhibitor of CDK5/p25 complex activity that can treat cancers (e.g., glioblastoma and colon cancer) causing abnormal regulation of central nervous system (CNS) processes. This technology has demonstrated dramatic increases in survival in mouse models and qualifies for FDA Fast Track and Orphan Drug Status in Glioblastoma (GBM).
GBM is the most aggressive form of brain cancer. The current standard of care against GBM is a combination of surgery, chemotherapy and radiotherapy. However, after standard treatment, the cancer usually recurs – emphasizing a need for new targets and better alternatives. A promising target is cyclin-dependent kinase 5 (CDK5), the hyperactivity of which has been shown to have a role in cancer progression.
TP5/TFP5, a small peptide inhibitor against CDK5, was developed at the National Institutes of Health and modified to increase its passage through the blood brain barrier. Researchers at the NCI and NINDS demonstrated that TP5 decreases cell viability and increases programmed cell death in GBM and CRC cell lines with aberrant CDK5 activity. TP5 was found to impair DNA repair by inhibiting CDK5 and acted additively and synergistically with DNA-damaging agents (e.g., temozolomide, irinotecan, irradiation) used in treatment of GBM and colon carcinoma. TP5 decreased the tumor volume and increased the overall survival of orthotopic glioblastoma mouse models.
This scientific presentation is an opportunity to license this technology, or participate in further collaborative work to enhance its development.
The Technology Evaluation Consortium, which plays a role in evaluating new technologies such as this, includes organizations such as Pfizer, AbbVie, Amgen and Allergan, and many others.
ABOUT ONE MILLION SOLUTIONS IN HEALTH
The goal of One Million Solutions in Health is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery of innovative cures, treatments and preventative measures for patients around the world.
In this next year through the Hidden GEMS Program, we will be reviewing 100's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.
We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research, and share patient and consumer-focused ideas and solutions.
As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey.
ABOUT the TECHNOLOGY EVALUATION CONSORTIUM and the HIDDEN GEMS PROGRAM
Through the Hidden GEMS Program, the Technology Evaluation Consortium from One Million Solutions in Health is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.
The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.
To obtain further information about licensing or co-development opportunities OR to have One Million Solutions in Health help your Technology Transfer office bring more of your research to market by obtaining more licensing deals via the Hidden GEMS Program, contact:
Dawn Van Dam, Executive Director
One Million Solutions in Health